3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione
3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione
3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione 性质
| 沸点 | 643.5±55.0 °C(Predicted) |
|---|---|
| 密度 | 1?+-.0.1 g/cm3(Predicted) |
| 储存条件 | room temp |
| 溶解度 | 在DMSO中的溶解度≥15mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 7.44±0.60(Predicted) |
| 颜色 | 浅橙色至深橙色粘性 |
3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione 用途与合成方法
|
GSK-3α 16 nM (IC 50 ) |
GSK-3β 21 nM (IC 50 ) |
BIP-135 (20-30 μM; 72 hours) increases the survival motor neuron (SMN) protein levels at a dose of 25 μM in human SMA fibroblasts. And the typical bell-shaped dose-response curve is observed due to some toxicity at higher concentrations.
BIP-135 (20 μM; 48 hours) is a superior neuroprotective agent in the model of oxidative stress.
Western Blot Analysis
| Cell Line: | Human SMA fibroblasts |
| Concentration: | 20 μM, 25 μM, 30 μM |
| Incubation Time: | 72 hours |
| Result: | Led to a 7-fold increase in SMN levels at 25 μM. |
BIP-135 does not appear to be toxic and was well-tolerated by the animals (no decrease in body weight).
BIP-135 (75 mg/kg; i.p.; daily; from postnatal day 0 to 21) prolongs the median survival time of Δ7 SMA KO mouse model of spinal muscular atrophy.
| Animal Model: | Male and female SMN2 +/+ , SMN2Δ7 +/+ , Smn +/– mice |
| Dosage: | 75 mg/kg |
| Administration: | Intraperitoneal injection; daily; from postnatal day 0 to 21 |
| Result: | Caused a modest extension in the median survival of SMA KO animals by two days. |
3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-111055 | 3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione | 941575-71-9 | 1mg | 480 |
| 2024-11-08 | HY-111055 | 3-(5-BroMo-1-Methyl-1H-indol-3-yl)-4-(benzofuran-3-yl)pyrrole-2,5-dione | 941575-71-9 | 5mg | 1250 |
